Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Trius Therapeutics
July 14, 2015
Interview – Dong-A shifts sights from Korea to the US
December 08, 2014
Merck snaps up Cubist in $9.5bn antibiotic play
October 07, 2014
Takeout of Durata shows antibiotics investment can pay dividends
May 07, 2014
Development-stage M&A premiums reward very patient investors
December 17, 2013
Cubist turns positive on good news from gram-negative antibiotic
July 31, 2013
Cubist right to inject caution into much-needed acquisition spree
March 26, 2013
For Trius the hard work is just beginning as filing looms
March 08, 2013
Event – Trius hopes tedizolid success is infectious
January 16, 2012
IPO hopefuls line up after woeful 2011
January 06, 2012
Small caps produce clear winners and losers in 2011
October 04, 2011
Pharmasset continues to lead small cap gainers so far in 2011
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
April 22, 2021
Evaluate Vantage Report: US Approvals Under the Spotlight
Editor's Picks
May 25, 2021
Lilly leads the big pharma pack on pipeline value
May 27, 2021
Go or no go? Aducanumab’s day of reckoning
May 26, 2021
Roche remains big pharma’s biggest R&D spender
June 03, 2021
Asco 2021 justifies Novartis’s radioligand Vision
June 09, 2021
Asco 2021 story roundup
